natgillin/translations-raw huggingface dataset:
Lynparza is not recommended for use in patients with severe renal impairment or end-stage renal disease (creatinine clearance ≤ 30 ml/min) since there are no data in such patients.
Primjena lijeka Lynparza se ne preporučuje kod bolesnica s teškim oštećenjem bubrežne funkcije ili u terminalnom stadiju bubrežne bolesti (klirens kreatinina ≤ 30 ml/min) jer ne postoje podaci kod takvih bolesnica.
Lynparza is used for the treatment of a type of ovarian cancer called “BRCA-mutated ovarian cancer”.
Lynparza se koristi za liječenje jedna vrste raka jajnika koji se naziva "rak jajnika s mutacijom BRCA gena".
Lynparza is used in patients who have mutations (defects) in one of the two genes known as BRCA1 and BRCA2 and who have recurrent disease (when the cancer has come back after previous treatment).
Lynparza se koristi u bolesnica koje imaju mutacije (nedostatke) u jednom od dva gena poznata pod nazivom BRCA1 i BRCA2 a koje imaju recidivnu bolest (slučajevi kada se karcinom ponovno pojavljuje nakon terapije).
Lynparza may only be used in patients with severe renal impairment if the benefit outweighs the potential risk, and the patient should be carefully monitored for renal function and adverse events.
Lynparza se smije koristiti u bolesnica s teškim oštećenjem bubrežne funkcije samo ako korist nadmašuje mogući rizik, a tada treba pažljivo nadzirati bubrežnu funkciju bolesnice i mogući nastup nuspojava.
Lynparza should be taken at least one hour after food and patients should not eat preferably for up to two hours afterwards.
Lijek Lynparza treba uzeti najmanje jedan sat nakon hrane, a bolesnice ne smiju jesti do dva sata nakon što su uzele lijek.
Lynparza should not be used during pregnancy and in women of childbearing potential not using reliable contraception during therapy and for 1 month after receiving the last dose of Lynparza (see section 4.6).
Lynparza se ne smije uzimati tijekom trudnoće niti kod žena reproduktivne dobi koje ne koriste pouzdanu kontracepciju tijekom liječenja i nakon još mjesec dana nakon primanja posljednje doze lijeka Lynparza (vidjeti dio 4.6).
Lynparza was given not later than 8 weeks after the last cycle of platinum-based medicines, when the tumour was diminishing in size or had completely disappeared.
Lynparza se nije primjenjivao nakon 8 tjedana od posljednjeg ciklusa lijekova koji se temelje na platini, nakon što je tumor nestao ili se smanjila veličina istog.
Lynparza with drink
Lynparza sa pićem
Lyophilisate
Liofilizat:
Lyophilisate (live attenuated)
Liofilizat (živi atenuirani)
Lyophilisate (live attenuated) Minimum Maximum
Liofilizat (živi atenuirani) Minimalno Maksimalno
Lyophilisate (live attenuated) Minimum Maximum
Liofilizat (živi atenuirani): Minimalno Maksimalno
Lyophilisate (white lyophilisate) Active substance:
Liofilizat (bijeli liofilizat) Djelatna tvar:
Lyophilisate : white pellet.
Liofilizat: bijela peleta.
Lyophilisate and solvent for oculonasal suspension
Liofilizat i otapalo za okulonazalnu suspenziju
Lyophilisate and solvent for solution for injection
Liofilizat i otapalo za otopinu za injekciju
Lyophilisate and solvent for suspension
Liofilizat i otapalo za suspenziju
Lyophilisate and solvent for suspension for injection
Liofilizat i otapalo
Lyophilisate and solvent for suspension for injection
Liofilizat i otapalo za suspenziju za injekcije
Lyophilisate and solvent for suspension for injection
Liofilizat i otapalo za suspenziju za injekciju Liofilizat: bjelkasta do krem peleta
Lyophilisate and solvent for suspension for injection
Liofilizat i otapalo za suspenziju za injekciju.
Lyophilisate and solvent for suspension for injection
Liofilizat i otapalo, suspenzija za injekciju
Lyophilisate and solvent for suspension for injection
Liofilizati i otapalo za suspenziju za injekciju
lyophilisate and solvent for suspension for injection for cats
Liofilizat i otapalo za suspenziju za injekciju namijenjeni mačkama
Lyophilisate and solvent for suspension for injection.
Liofilizat i otapalo za suspenziju za injekciju
Lyophilisate and solvent for suspension for injection.
Liofilizat i otapalo, suspenzija za injekciju.
Lyophilisate and solvent for suspension or lyophilisate for suspension.
Liofilizat i otapalo za suspenziju ili liofilizat za supenziju..
Lyophilisate and solvent for suspension..
Liofilizat i otapalo za suspenziju
Lyophilisate bottle
Bočica s liofilizatom
Lyophilisate CUPS
Liofilizat ČAŠICE
Lyophilisate CUPS
ČAŠICE liofilizata
Lyophilisate for oral suspension
Liofilizat za oralnu suspenziju
lyophilisate for oral suspension for pigs
liofilizat za peroralnu suspenziju za svinje
Lyophilisate for suspension
liofilizat za rekonstituiranje
Lyophilisate for suspension
Liofilizat za suspenziju
Lyophilisate for suspension
Liofilizat za suspenziju.
Lyophilisate for suspension for injection
Liofilizat i otapalo za suspenziju za injekciju
Lyophilisate for suspension for spray
Liofilizat za suspenziju za sprej
Lyophilisate for suspension for spray vaccination and for use in drinking water
Liofilizat za suspenziju za vakcinaciju raspršivanjem ili putem vode za piće
Lyophilisate for suspension for spray vaccination or for use in drinking water
Liofilizat za suspenziju za vakcinaciju raspršivanjem ili vodom za piće.
Lyophilisate for suspension for spray vaccination or for use in drinking water.
Liofilizat za suspenziju za vakcinaciju raspršivanjem ili putem vode za piće.
Lyophilisate Urea,
Liofilizat urea,
Lyophilisate vial
Bočica liofilizata
LYOPHILISATE VIAL
Bočica s liofilizatom
Lyophilisate vial
Bočica za liofilizat
Lyophilisate vial label (10 and 50 doses)
Etiketa bočice s liofilizatom (10 i 50 doza)
Lyophilisate VIALS
Liofilizat BOČICE
Lyophilisate vials: 5 doses, 10 doses and 25 doses
Bočice s liofilizatom: 5 doza, 10 doza i 25 doza
Lyophilisate vials: 50 doses
Bočice s liofilizatom: 50 doza
Lyophilisate: 1 dose;
Liofilizat: 1 doza
Lyophilisate: 1 dose; solvent: 0.8 ml
Liofilizat: 1 doza; otapalo: 0,8 ml
Lyophilisate: 1 vial; solvent: 1 vial
Liofilizat: 1 bočica; otapalo: 1 bočica
Lyophilisate: 10 doses, solvent:
Liofilizat: 10 doza,
Lyophilisate: 10 doses; solvent: 10 ml
Liofilizat: 10 doza; otapalo: 10 ml
Lyophilisate: 10 vials;
Liofilizat: 10 bocica
Lyophilisate: 10 vials;
Liofilizat: 10 bočica
Lyophilisate: 10 vials; solvent:
Liofilizat: 10 bočica;
Lyophilisate: 25 doses, solvent:
Liofilizat: 25 doza,
Lyophilisate: 25 doses; solvent: 50 ml
Liofilizat: 25 doza; otapalo: 50 ml
Lyophilisate: 25 vials;
Liofilizat: 25 bocica ;
Lyophilisate: 30 doses; solvent: 60 ml
Liofilizat: 30 doza; otapalo: 60 ml
Lyophilisate: 5 doses, solvent:
Liofilizat: 5 doza,
Lyophilisate: 5 doses; solvent: 10 ml
Liofilizat: 5 doza; otapalo: 10 ml
Lyophilisate: 50 doses, solvent:
Liofilizat: 50 doza,
Lyophilisate: 50 doses;
Liofilizat: 50 doza
Lyophilisate: 50 doses; solvent: 50 ml
Liofilizat: 50 doza; otapalo: 50 ml
Lyophilisate: 6 x 1 dose
Liofilizat: 6 x 1 doza
Lyophilisate: bottle (type I glass); solvent: bottle (type I glass or PET)
Liofilizat: bocu (stakla tipa I); otapalo: bocu (stakla tipa I ili PET)
Lyophilisate: bottle (type I glass); solvent: bottle (type II glass or PET)
Liofilizat: bocu (stakla tipa I); otapalo: bocu (stakla tipa II ili PET)
Lyophilisate: bromobutyl rubber stoppers and aluminium caps
Liofilizat: bromobutilni gumeni čepovi i aluminijske kapice
Lyophilisate: cup (Alu/PP); Solvent: vial (LDPE)
Liofilizat : (Alu/PP); Otapalo : bočica (LDPE)
Lyophilisate: Off-white or cream-coloured pellet Solvent: clear colourless solution
Liofilizat: bezbojna do bjelkasta peleta Otapalo: bistra bezbojna otopina
Lyophilisate: off-white or cream-coloured pellet Solvent: clear colourless solution
Otapalo: bistra bezbojna otopina
Lyophilisate: spongy matter of white colour
Liofilizat: spužvasta tvorba bijele boje.
Lyophilisate: spongy matter of white colour.
Liofilizat: spužvasta tvorba bijele boje.
Lyophilisate: Store and transport refrigerated (2 °C – 8 °C).
Liofilizat: Čuvati i prevoziti rashlađeno (2 °C – 8 °C).
Lyophilisate: Store in a refrigerator (2 C – 8 C).
Liofilizat: Čuvati u hladnjaku (2 C – 8 C).
Lyophilisate: Store in a refrigerator (2 C – 8 C).
Liofilizat: Čuvati u hladnjaku (2°C-8°C).
Lyophilisate: Trometamol
Liofilizat: Trometamol
Lyophilisate: vial (glass); solvent: vial (glass)
Liofilizat: bočica (staklo); otapalo: bočica (staklo)
Lyophilised formulation of palivizumab
Liofilizirani oblik palivizumaba
Lyrica 100 mg hard capsules EU/1/04/279/014-016 EU/1/04/279/39
Lyrica 100 mg tvrde kapsule EU/1/04/279/014-016 EU/1/04/279/39
Lyrica 150 mg hard capsules EU/1/04/279/017-019 EU/1/04/279/028 EU/1/04/279/031 EU/1/04/279/040
Lyrica 150 mg tvrde kapsule EU/1/04/279/017-019 EU/1/04/279/028 EU/1/04/279/031 EU/1/04/279/040
Lyrica 20 mg/ml oral solution
Lyrica 20 mg/ml oralna otopina
Lyrica 200 mg hard capsules EU/1/04/279/020 – 022 EU/1/04/279/041
Lyrica 200 mg tvrde kapsule EU/1/04/279/020 – 022 EU/1/04/279/041
Lyrica 225 mg hard capsules EU/1/04/279/033 – 035 EU/1/04/279/042
Lyrica 225 mg tvrde kapsule EU/1/04/279/033 – 035 EU/1/04/279/042
Lyrica 225 mg hard capsules Pregabalin
Lyrica 225 mg tvrde kapsule Pregabalin
Lyrica 25 mg hard capsules EU/1/04/279/001-005 EU/1/04/279/026 EU/1/04/279/036
Lyrica 25 mg tvrde kapsule EU/1/04/279/001-005 EU/1/04/279/026 EU/1/04/279/036
Lyrica 25 mg, 50 mg, 150 mg hard capsules
Lyrica 25 mg, 50 mg, 150 mg tvrde kapsule Sadržaj kapsule:
Lyrica 300 mg hard capsules EU/1/04/279/023 – 025 EU/1/04/279/029 EU/1/04/279/032 EU/1/04/279/043
Lyrica 300 mg tvrde kapsule EU/1/04/279/023 – 025 EU/1/04/279/029 EU/1/04/279/032 EU/1/04/279/043
Lyrica 50 mg hard capsules EU/1/04/279/006-010 EU/1/04/279/037
Lyrica 50 mg tvrde kapsule EU/1/04/279/006-010 EU/1/04/279/037
Lyrica 75 mg hard capsules EU/1/04/279/011-013 EU/1/04/279/027 EU/1/04/279/030 EU/1/04/279/038 EU/1/04/279/045
Lyrica 75 mg tvrde kapsule EU/1/04/279/011-013 EU/1/04/279/027 EU/1/04/279/030 EU/1/04/279/038 EU/1/04/279/045
Lyrica capsules may be taken with or without food.
Lyrica kapsule mogu se uzimati s hranom ili bez nje.
Lyrica has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients.
Liječenje lijekom Lyrica povezuje se s pojavom omaglice i pospanosti, što može povećati broj slučajnih ozljeda (padova) u starijih bolesnika.
Lyrica is available in eight pack sizes made of PVC with an aluminium foil backing: a 14 capsules pack containing 1 blister strip, a 21 capsules pack containing 1 blister strip, a 56 capsules pack containing 4 blister strips, a 70 capsules pack containing 5 blister strips, a 84 capsules pack containing 4 blister strips, a 100 capsules pack containing 10 blister strips, a 112 (2 x 56) capsules pack and 100 x 1 capsules as perforated unit dose blisters.
Lyrica je dostupna u osam veličina pakiranja u PVC blisterima s pokrovom od aluminijske folije: pakiranje od 14 kapsula u 1 blisteru, pakiranje od 21 kapsule u 1 blisteru, pakiranje od 56 kapsula u 4 blistera, pakiranje od 70 kapsula u 5 blistera, pakiranje od 84 kapsule u 4 blistera, pakiranje od 100 kapsula u 10 blistera, pakiranje od 112 (2 x 56) kapsula i pakiranje od 100 x 1 kapsule u perforiranom blisteru djeljivom na jedinične doze.
Lyrica is for oral use only.
Lyrica je namijenjena samo za primjenu kroz usta.
Lyrica is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Lyrica je indicirana za liječenje generaliziranog anksioznog poremećaja (GAP) u odraslih osoba.
Lyrica is indicated for the treatment of peripheral and central neuropathic pain in adults.
Lyrica je indicirana za liječenje periferne i centralne neuropatske boli u odraslih osoba.
Lyrica may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary.
Lyrica može uzrokovati zamagljen vid, gubitak vida ili druge promjene vida, od kojih su mnoge privremene.
Lyrica oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).
Lyrica oralna otopina sadrži metilparahidroksibenzoat i propilparahidroksibenzoat koji mogu izazvati alergijske reakcije (moguće i kasne).
Lyrica with food, drink and alcohol
Lyrica s hranom, pićem i alkoholom
Lysine hydrochloride Polysorbate 80
Lizinklorid Polisorbat 80
Lysodren (Braille applies only to outer carton)
Lysodren (Braille se navodi samo na kutiji)
Lysodren 500 mg tablets
Lysodren 500 mg tablete mitotan
Lysodren 500 mg tablets Mitotane
Lysodren 500 mg tablete mitotan
LYSODREN PATIENT CARD
LYSODREN KARTICA ZA BOLESNIKA
Lysodren should preferably be taken during meals containing fat-rich food such as milk, chocolate, oil.
Lysodren je poželjno uzimati uz obrok hrane bogate mastima kao što su mlijeko, čokolada, ulje.
Lysodren with food and drink
Lysodren s hranom i pićem
Lyxumia 10 mcg injection lixisenatide
Lyxumia 10 µg injekcija liksisenatid
Lyxumia 10 micrograms solution for injection
Lyxumia 10 mikrograma otopina za injekciju
Lyxumia 10 micrograms solution for injection is available for the starting dose.
Za početnu je dozu dostupna Lyxumia 10 mikrograma otopina za injekciju.
Lyxumia 10 micrograms solution for injection lixisenatide
Lyxumia 10 mikrograma otopina za injekciju liksisenatid
Lyxumia 10 micrograms solution for injection Lyxumia 20 micrograms solution for injection
Lyxumia 10 mikrograma otopina za injekciju Lyxumia 20 mikrograma otopina za injekciju
Lyxumia 20 mcg injection lixisenatide
Lyxumia 20 µg injekcija liksisenatid
Lyxumia 20 micrograms solution for injection
Lyxumia 20 mikrograma otopina za injekciju
Lyxumia 20 micrograms solution for injection is available for the maintenance dose.
Za dozu održavanja dostupna je Lyxumia 20 mikrograma otopina za injekciju.
Lyxumia 20 micrograms solution for injection lixisenatide
Lyxumia 20 mikrograma otopina za injekciju liksisenatid
Lyxumia given with a basal insulin alone, or with a combination of a basal insulin and metformin, or a combination of a basal insulin and a sulphonylurea resulted in statistically significant reductions in HbA1c and in 2-hour post-prandial glucose after a test-meal compared to placebo.
Kada se Lyxumia primjenjivala samo s bazalnim inzulinom ili u kombinaciji s bazalnim inzulinom i metforminom ili u kombinaciji s bazalnim inzulinom i sulfonilurejom, došlo je do statistički značajnog smanjenja vrijednosti HbA1c i glukoze postprandijalno 2 sata nakon testnog obroka u usporedbi s placebom.
Lyxumia has no or negligible influence on the ability to drive or use machines.
Lyxumia ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Lyxumia is a clear and colourless solution for injection (injection) filled in a glass cartridge inserted in a pre-filled pen.
Lyxumia je bistra i bezbojna otopina za injekciju (injekcija) u staklenom ulošku koji je umetnut u napunjenu brizgalicu.
Lyxumia is administered once daily, within the hour prior to any meal of the day.
Lyxumia se primjenjuje jedanput na dan, unutar sat vremena prije bilo kojeg dnevnog obroka.
Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4 and 5.1 for available data on the different combinations).
Lyxumia je indicirana za liječenje odraslih sa šećernom bolešću tipa 2 za postizanje kontrole glikemije u kombinaciji s oralnim lijekovima za snižavanje razine glukoze u krvi i/ili bazalnim inzulinom kada ti lijekovi u kombinaciji s dijetom i tjelovježbom ne omogućuju odgovarajuću kontrolu glikemije (vidjeti dijelove 4.4 i 5.1 za dostupne podatke o različitim kombinacijama).
Lyxumia is not recommended in women of childbearing potential not using contraception.
Lyxumia se ne preporučuje u žena reproduktivne dobi koje ne primjenjuju kontracepciju.
Lyxumia is to be injected subcutaneously in the thigh, abdomen or upper arm.
Lyxumia se injicira supkutano u bedro, abdomen ili nadlakticu.
Lyxumia should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption, require careful clinical monitoring or have a narrow therapeutic ratio.
Lyxumia se mora primjenjivati s oprezom u bolesnika koji uzimaju peroralne lijekove koji zahtijevaju brzu gastrointestinalnu apsorpciju, pomno kliničko praćenje ili koji imaju uzak terapijski indeks.
Lyxumia should not be administered intravenously or intramuscularly.
Lyxumia se ne smije primjenjivati intravenski ili intramuskularno.
Lyxumia should not be given in combination with basal insulin and a sulphonylurea due to increased risk of hypoglycaemia.
Lyxumia se ne smije primjenjivati u kombinaciji s bazalnim inzulinom i sulfonilurejom zbog povećanog rizika od hipoglikemije.
Lyxumia should not be used if breast-feeding.
Lyxumia se ne smije primjenjivati tijekom dojenja.
Lévai u.5.
Lévai u.5.‌
m 48 weeks of double-blind adefovir dipivoxil followed by 240 weeks open-label tenofovir disoproxil fumarate. n Figures presented are cumulative percentages based upon a Kaplan Meier analysis excluding data collected after the addition of emtricitabine to open-label tenofovir disoproxil fumarate (KM-TDF).
m 48 tjedana dvostruko slijepog ispitivanja adefovirdipivoksila nakon čega slijedi 240 jedana otvorenog ispitivanja tenofovirdizoproksilfumarata. n Prikazani brojevi su kumulativni postotci koji se temelje na Kaplan-Meierovoj analizi isključujući podatke prikupljene nakon dodavanja emtricitabina otvorenom liječenju tenofovirdizorproksil fumaratom (KM-TDF).
m 48 weeks of double-blind adefovir dipivoxil followed by 240 weeks open-label tenofovir disoproxil fumarate. n Figures presented are cumulative percentages based upon a Kaplan Meier analysis excluding data collected after the addition of emtricitabine to open-label tenofovir disoproxil fumarate (KM-TDF).
m 48 tjedana dvostruko slijepog ispitivanja adefovirdipivoksila nakon čega slijedi 240 tjedana otvorenog ispitivanja tenofovirdizoproksilfumarata. n Prikazani brojevi su kumulativni postotci koji se temelje na Kaplan-Meierovoj analizi isključujući podatke prikupljene nakon dodavanja emtricitabina otvorenom liječenju tenofovirdizorproksil fumaratom (KM-TDF).
m including injection site pain, infusion-site discomfort n including infusion-site pruritus, infusion-site erythema
m uključujući bol na mjestu injekcije, nelagodu na mjestu infuzije n uključujući pruritus na mjestu infuzije, eritem na mjestu infuzije o uključujući bol u prsima i stezanje u prsima p To je doslovan pojam kako je prijavljeno.
m-Cresol [3.15 mg/ml] Glycerol
metakrezol [3,15 mg/ml] glicerol
M-M- RVAXPRO is not to be injected directly into any blood vessel.
M-M-RVAXPRO se ne smije injicirati izravno u krvnu žilu.
M-M- RVAXPRO must not be given during pregnancy, any illness with fever (over 38.5°C) or active untreated tuberculosis (TB).
M-M- RVAXPRO ne smije se davati tijekom trudnoće, bilo koje bolesti s vrućicom (iznad 38,5°C) ili aktivnom neliječenom tuberkulozom (TB).
M-M-RVAXPRO (or its component vaccines) may develop thrombocytopenia with repeat doses.
M-M-RVAXPRO (ili cjepiva s nekom od njegovih komponenata) mogu razviti trombocitopeniju na ponovljenu dozu.
M-M-RVAXPRO - Powder in vial and solvent in pre-filled syringe with one unattached needle – Pack of 1, 10, 20
M-M-RVAXPRO - Prašak u bočici i otapalo u napunjenoj štrcaljki s jednom iglom koja nije pričvršćena na štrcaljku -Pakiranje od 1, 10, 20
M-M-RVAXPRO - Powder in vial and solvent in pre-filled syringe with two unattached needles - Pack of 1, 10, 20
M-M-RVAXPRO - Prašak u bočici i otapalo u napunjenoj štrcaljki s dvije igle koje nisu pričvršćene na štrcaljku -Pakiranje od 1, 10, 20
M-M-RVAXPRO - Powder in vial and solvent in prefilled syringe with attached needle - Pack of 1, 10
M-M-RVAXPRO - Prašak u bočici i otapalo u napunjenoj štrcaljki s pričvršćenom iglom - Pakiranje od 1, 10
M-M-RVAXPRO - Powder in vial and solvent in prefilled syringe without needle - Pack of 1, 10, 20
M-M-RVAXPRO - Prašak u bočici i otapalo u napunjenoj štrcaljki bez igle -Pakiranje od 1, 10, 20
M-M-RVAXPRO contains small amounts of weakened forms of the viruses that cause measles, mumps, and rubella.
M-M-RVAXPRO sadrži male količine oslabljenih oblika virusa koji uzrokuju morbile, parotitis i rubeolu.
M-M-RVAXPRO contains sorbitol.
M-M-RVAXPRO sadrži sorbitol
M-M-RVAXPRO has not been evaluated in fertility studies.
M-M-RVAXPRO nije procjenjivan u ispitivanjima plodnosti.
M-M-RVAXPRO is a vaccine that contains live attenuated (weakened) measles, mumps and rubella viruses.
M-M-RVAXPRO je cjepivo koje sadrži žive, atenuirane (oslabljene) virusemorbila, parotitisa i rubele.
M-M-RVAXPRO is a vaccine.
M-M-RVAXPRO je cjepivo.
M-M-RVAXPRO is given according to official recommendations.
M-M-RVAXPRO se daje u skladu sa službenim preporukama.
M-M-RVAXPRO is preferred for vaccination of persons likely to be susceptible to mumps and rubella.
M-M-RVAXPRO cjepivo je poželjno za cijepljenje osoba koje su vjerojatno podložne infekciji parotitisom i rubelom.
M-M-RVAXPRO is used to vaccinate against measles, mumps, and rubella (German measles) in adults and children aged 12 months or older.
M-M-RVAXPRO koristi se za cijepljenje protiv morbila, parotitisa i rubeole (njemački morbili) u odraslih i djece u dobi od 12 mjeseci i starijih.
M-M-RVAXPRO is very similar to another vaccine for the measles, mumps and rubella vaccine already authorised (M-M-R II) but with a slight difference.
M-M-RVAXPRO je vrlo sličan drugom cjepivu protiv morbila, parotitisa i rubeole koje je već odobreno (M-M-R II) ali je ipak nešto različito.
M-M-RVAXPRO may be given with Prevenar and/or hepatitis A vaccine at the same visit at a separate injection site (e.g. the other arm or leg).
M-M-RVAXPRO se može primijeniti istodobno s cjepivom Prevenar i/ili cjepivom protiv hepatitisa A, ali na različito mjesto primjene (npr. u drugu ruku ili nogu).
M-M-RVAXPRO powder and solvent for suspension for injection in pre-filled syringe Measles, mumps, and rubella vaccine (live)
M-M-RVAXPRO prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki Cjepivo protiv morbila, parotitisa i rubele (živo)
M-M-RVAXPRO should be injected into the muscle or under the skin either in the area of the outer thigh or of the upper arm.
M-M-RVAXPRO se mora primijeniti injekcijom u mišić ili potkožno, u vanjsku stranu natkoljenice ili u nadlakticu.
M-M-RVAXPRO should not be used in people who may be hypersensitive (allergic) to any measles, mumps or rubella vaccine, or to any of the ingredients, including neomycin (an antibiotic).
M-M-RVAXPRO ne smije se koristiti u ljudi koji mogu biti preosjetljivi (alergični) na cjepivo protiv morbila, parotitisa ili rubeole ili na bilo koji od sastojaka uključujući i neomicin (antibiotik).
M. catarrhalis: S ≤ 0.5 mg/L and R > 0.5 mg/L
M. catarrhalis: S ≤0,5 mg/l i R >0,5 mg/l
M. hyopneumoniae inac.  2.69 RPU.
M. hyopneumoniae inac. ≥ 2,69 RPU.
M. synoviae strain MS-H
M. synoviae soj MS-H
M06-802 was a randomised open-label study comparing the safety, tolerability and antiviral activity of once daily and twice daily dosing of lopinavir/ritonavir tablets in 599 subjects with detectable viral loads while receiving their current antiviral therapy.
M06-802 je bilo randomizirano, otvoreno ispitivanje koje je uspoređivalo sigurnost, podnošljivost i antivirusnu aktivnost kod doziranja lopinavir/ritonavir tableta jednom dnevno i doziranja dva puta dnevno kod 599 ispitanika s mjerljivom količinom virusa za vrijeme primanja njihove antivirusne terapije.
M06-802 was a randomised open-label study comparing the safety, tolerability and antiviral activity of once-daily and twice-daily dosing of lopinavir/ritonavir tablets in 599 subjects with detectable viral loads while receiving their current antiviral therapy.
M06-802 je bilo randomizirano, otvoreno ispitivanje koje je uspoređivalo sigurnost, podnošljivost i antivirusnu aktivnost kod doziranja lopinavir/ritonavir tableta jednom dnevno i doziranja dva puta dnevno kod 599 bolesnika s mjerljivom količinom virusa za vrijeme primanja njihove antivirusne terapije.